Rahel Frick

Rahel Frick

Auto-generated profile, based on publicly available information

Rahel Frick

Department of Chemical and Biomolecular Engineering The Johns Hopkins University Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JJJeliazko R. Jeliazkov
Jeliazko R. Jeliazkov
RFRahel Frick
Rahel Frick
JZJing Zhou
Jing Zhou
JGJeffrey J. Gray
Jeffrey J. Gray
In recent years, the observed antibody sequence space has grown exponentially due to advances in high-throughput sequencing of immune receptors. The rise in sequences has not been mirrored by a rise in structures, as experimental structure determination techniques have remained low-throughput. Computational modeling, however, has the potential to close the sequence–structure gap. To achieve this goal, computational methods must be robust, fast, easy to use, and accurate. Here we report on the latest advances made in RosettaAntibody and Rosetta SnugDock—methods for antibody structure prediction and antibody–antigen docking. We simplified the user interface, expanded and automated the template database, generalized the kinematics of antibody–antigen docking (which enabled modeling of single-domain antibodies) and incorporated new loop modeling techniques. To evaluate the effects of our updates on modeling accuracy, we developed rigorous tests under a new scientific benchmarking framework within Rosetta. Benchmarking revealed that more structurally similar templates could be identified in the updated database and that SnugDock broadened its applicability without losing accuracy. However, there are further advances to be made, including increasing the accuracy and speed of CDR-H3 loop modeling, before computational approaches can accurately model any antibody.

18 August 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
TGTorleif Tollefsrud Gjølberg
Torleif Tollefsrud Gjølberg
RFRahel Frick
Rahel Frick
SMSimone Mester
Simone Mester
SFStian Foss
Stian Foss
AGAlgirdas Grevys
Algirdas Grevys
JAJan Terje Andersen
Jan Terje Andersen
Antibody-based therapeutics (ABTs) are used to treat a range of diseases. Most ABTs are either full-length IgG1 antibodies or fusions between for instance antigen (Ag)-binding receptor domains and the IgG1 Fc fragment. Interestingly, their plasma half-life varies considerably, which may relate to how they engage the neonatal Fc receptor (FcRn). As such, there is a need for an in-depth understanding of how different features of ABTs affect FcRn-binding and transport behavior. Here, we report on how FcRn-engagement of the IgG1 Fc fragment compare to clinically relevant IgGs and receptor domain Fc fusions, binding to VEGF or TNF-α. The results reveal FcRn-dependent intracellular accumulation of the Fc, which is in line with shorter plasma half-life than that of full-length IgG1 in human FcRn-expressing mice. Receptor domain fusion to the Fc increases its half-life, but not to the extent of IgG1. This is mirrored by a reduced cellular recycling capacity of the Fc-fusions. In addition, binding of cognate Ag to ABTs show that complexes of similar size undergo cellular transport at different rates, which could be explained by the biophysical properties of each ABT. Thus, the study provides knowledge that should guide tailoring of ABTs regarding optimal cellular sorting and plasma half-life.

10 August 2021 in Science Immunology
Verified
Journal Article
Closed access
RFRahel Frick
Rahel Frick
LHLene Støkken Høydahl
Lene Støkken Høydahl
JPJan Petersen
Jan Petersen
MPM. Fleur du Pré
M. Fleur du Pré
SKShraddha Kumari
Shraddha Kumari
GLGeir Åge Løset
Geir Åge Løset
A human TCR-like antibody blocks gluten-dependent activation of celiac disease T cells in vitro and in HLA-DQ2.5 humanized mice.

21 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
SMSai Pooja Mahajan
Sai Pooja Mahajan
JRJeffrey A. Ruffolo
Jeffrey A. Ruffolo
RFRahel Frick
Rahel Frick
JGJeffrey J. Gray
Jeffrey J. Gray
Antibodies are widely developed and used as therapeutics to treat cancer, infectious disease, and inflammation. During development, initial leads routinely undergo additional engineering to increase their target affinity. Experimental methods for affinity maturation are expensive, laborious, and time-consuming and rarely allow the efficient exploration of the relevant design space. Deep learning (DL) models are transforming the field of protein engineering and design. While several DL-based protein design methods have shown promise, the antibody design problem is distinct, and specialized models for antibody design are desirable. Inspired by hallucination frameworks that leverage accurate structure prediction DL models, we propose the FvHallucinator for designing antibody sequences, especially the CDR loops, conditioned on an antibody structure. Such a strategy generates targeted CDR libraries that retain the conformation of the binder and thereby the mode of binding to the epitope on the antigen. On a benchmark set of 60 antibodies, FvHallucinator generates sequences resembling natural CDRs and recapitulates perplexity of canonical CDR clusters. Furthermore, the FvHallucinator designs amino acid substitutions at the VH-VL interface that are enriched in human antibody repertoires and therapeutic antibodies. We propose a pipeline that screens FvHallucinator designs to obtain a library enriched in binders for an antigen of interest. We apply this pipeline to the CDR H3 of the Trastuzumab-HER2 complex to generate in silico designs predicted to improve upon the binding affinity and interfacial properties of the original antibody. Thus, the FvHallucinator pipeline enables generation of inexpensive, diverse, and targeted antibody libraries enriched in binders for antibody affinity maturation.

3 April 2023 in Heliyon
Verified
Journal Article
Open access
NHNancy Hernandez
Nancy Hernandez
WJWojciech Jankowski
Wojciech Jankowski
RFRahel Frick
Rahel Frick
SKSimon P. Kelow
Simon P. Kelow
JLJoseph H. Lubin
Joseph H. Lubin
ZSZuben E. Sauna
Zuben E. Sauna
The human infectious disease COVID-19 caused by the SARS-CoV-2 virus has become a major threat to global public health. Developing a vaccine is the preferred prophylactic response to epidemics and pandemics. However, for individuals who have contracted the disease, the rapid design of antibodies that can target the SARS-CoV-2 virus fulfils a critical need. Further, discovering antibodies that bind multiple variants of SARS-CoV-2 can aid in the development of rapid antigen tests (RATs) which are critical for the identification and isolation of individuals currently carrying COVID-19. Here we provide a proof-of-concept study for the computational design of high-affinity antibodies that bind to multiple variants of the SARS-CoV-2 spike protein using RosettaAntibodyDesign (RAbD). Well characterized antibodies that bind with high affinity to the SARS-CoV-1 (but not SARS-CoV-2) spike protein were used as templates and re-designed to bind the SARS-CoV-2 spike protein with high affinity, resulting in a specificity switch. A panel of designed antibodies were experimentally validated. One design bound to a broad range of variants of concern including the Omicron, Delta, Wuhan, and South African spike protein variants.

15 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DADiego del Alamo
Diego del Alamo
RFRahel Frick
Rahel Frick
DTDaphne Truan
Daphne Truan
JKJoel Karpiak
Joel Karpiak
The neural network ProteinMPNN designs protein sequences capable of folding into predefined tertiary structures and quaternary assemblies. It has become widely used due to its high success rates when working with synthetic topologies rich in secondary structure. Here, we show degraded performance on the complementarity-determining regions (CDRs) of antibodies, with designs frequently failing to resemble native antibodies or failing to refold into the designed conformations. We also show that this underperformance can be rescued by ensembling its predictions with those from the antibody-specific protein language model AbLang, which designs exclusively using sequence information learned from large databases of antibody sequences. Finally, we tested 96 trastuzumab variants with CDRH3 loops redesigned by the ensembled ProteinMPNN+AbLang method and found that it generated thirty-six HER2 binders, compared to three out of 96 designs generated by ProteinMPNN alone. The data highlight the value of incorporating additional restraints derived from language models during structure-based sequence design of antibodies.